Amicus Therapeutics Germany News and Activities

Amicus Therapeutics Germany is owned by Biomarin Pharmaceutical.

Biomarin Pharmaceutical is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Biomarin Pharmaceutical is a company listed under the stock ticker BMRN (US).

Biomarin Pharmaceutical has a direct presence in 5 countries.

Biomarin Pharmaceutical has 6 subsidiaries including Amicus Therapeutics, Amicus Therapeutics France and Amicus Therapeutics Germany.

They are in:

• Biotechnology86%
• Pharmaceuticals14%

Acquisition, funding and merger involving Biomarin Pharmaceutical.

• Biomarin Pharmaceutical has acquired Amicus Therapeutics (posted on April 27 2026).
• Biomarin Pharmaceutical has just announced a $82 Million fundraising (posted on January 30 2026).
• Biomarin Pharmaceutical has announced the acquisition of Amicus Therapeutics  (posted on December 22 2025).
• Biomarin Pharmaceutical has announced the acquisition of Inozyme  (posted on May 29 2025).
• See more news about Biomarin Pharmaceutical Hide news involving Biomarin Pharmaceutical

View the org chart displaying its 4 main executives

Most searched biographies at Amicus Therapeutics Germany

• Ana Rogovic, Vice President, International Affiliates
• Assad Meyer, Director and Country Manager, Switzerland
• Vanessa Ruth Tejada, Commercial Project Manager

Popular executive movements at Biomarin Pharmaceutical

• Richard Meier, Chairman of the Board, will retire on Jun. 2, 2026  (posted on April 22 2026).
• Ian Clark who is Director, will become Chairman of the Board on Jun. 2, 2026  (posted on April 22 2026).
• Arpit Davé has joined the company as Chief Digital and Information Officer  (posted on January 13 2026).

Create your alert
to follow the executive moves at Amicus Therapeutics Germany.

Biomarin Pharmaceutical has 2,405 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Amicus Therapeutics Germany

• Morbus Fabry | AmicusRX Therapeutics
• Morbus Pompe | AmicusRX TherapeuticsBack ButtonSearch IconFilter Icon

Social media about Amicus Therapeutics Germany

• Amicus Therapeutics Germany on Wikipedia, Google News & Yahoo Finance
• Amicus Therapeutics Germany on LinkedIn, X (Twitter) & YouTube